JP Morgan Chase’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-276,551
| Closed | -$61.1M | – | 7568 |
|
|
2025
Q4 | $61.1M | Buy |
276,551
+245,880
| +802% | +$39.7M | ﹤0.01% | 1232 |
|
|
2025
Q3 | $2.94M | Buy |
30,671
+22,718
| +286% | +$1.45M | ﹤0.01% | 3788 |
|
|
2025
Q2 | $387K | Buy |
7,953
+7,947
| +132,450% | +$191K | ﹤0.01% | 4909 |
|
|
2025
Q1 | $129 | Hold |
6
| – | – | ﹤0.01% | 6849 |
|
|
2024
Q4 | $161 | Sell |
6
-100
| -94% | -$1.63K | ﹤0.01% | 6940 |
|
|
2024
Q3 | $1.14K | Hold |
106
| – | – | ﹤0.01% | 6707 |
|
|
2024
Q2 | $1.27K | Buy |
106
+83
| +361% | +$1.14K | ﹤0.01% | 6583 |
|
|
2024
Q1 | $415 | Sell |
23
-49
| -68% | -$704 | ﹤0.01% | 6744 |
|
|
2023
Q4 | $1.14K | Buy |
72
+55
| +324% | +$883 | ﹤0.01% | 6819 |
|
|
2023
Q3 | $315 | Sell |
17
-2
| -11% | -$39 | ﹤0.01% | 6785 |
|
|
2023
Q2 | $432 | Buy |
19
+13
| +217% | +$306 | ﹤0.01% | 6557 |
|
|
2023
Q1 | $0 | Sell |
6
-5
| -45% | -$142 | ﹤0.01% | 6734 |
|
|
2022
Q4 | $0 | Sell |
11
-1
| -8% | -$12 | ﹤0.01% | 6580 |
|
|
2022
Q3 | $0 | Buy |
12
+1
| +9% | +$14 | ﹤0.01% | 6485 |
|
|
2022
Q2 | $0 | Buy |
11
+5
| +83% | +$62 | ﹤0.01% | 6494 |
|
|
2022
Q1 | $0 | Sell |
6
-505
| -99% | -$8.57K | ﹤0.01% | 6626 |
|
|
2021
Q4 | $13K | Buy |
511
+383
| +299% | +$11.9K | ﹤0.01% | 6286 |
|
|
2021
Q3 | $5K | Sell |
128
-3,056
| -96% | -$116K | ﹤0.01% | 6245 |
|
|
2021
Q2 | $128K | Sell |
3,184
-1,869
| -37% | -$79.1K | ﹤0.01% | 5450 |
|
|
2021
Q1 | $269K | Buy |
5,053
+279
| +6% | +$13.8K | ﹤0.01% | 5025 |
|
|
2020
Q4 | $191K | Buy |
4,774
+4,117
| +627% | +$205K | ﹤0.01% | 4822 |
|
|
2020
Q3 | $38K | Buy |
657
+95
| +17% | +$6.71K | ﹤0.01% | 5013 |
|
|
2020
Q2 | $41K | Buy |
+562
| New | +$36.4K | ﹤0.01% | 4882 |
|
|
2019
Q4 | – | Sell |
-46
| Closed | -$2K | – | 5621 |
|
|
2019
Q3 | $2K | Sell |
46
-2,347
| -98% | -$78.9K | ﹤0.01% | 5620 |
|
|
2019
Q2 | $75K | Sell |
2,393
-379
| -14% | -$15.7K | ﹤0.01% | 5021 |
|
|
2019
Q1 | $147K | Sell |
2,772
-3,620
| -57% | -$198K | ﹤0.01% | 4742 |
|
|
2018
Q4 | $300K | Sell |
6,392
-1,061
| -14% | -$75.7K | ﹤0.01% | 4394 |
|
|
2018
Q3 | $656K | Buy |
7,453
+3,500
| +89% | +$309K | ﹤0.01% | 4148 |
|
|
2018
Q2 | $411K | Buy |
3,953
+494
| +14% | +$46.6K | ﹤0.01% | 4259 |
|
|
2018
Q1 | $277K | Buy |
3,459
+1,609
| +87% | +$220K | ﹤0.01% | 4248 |
|
|
2017
Q4 | $252K | Sell |
1,850
-213
| -10% | -$32.3K | ﹤0.01% | 4329 |
|
|
2017
Q3 | $328K | Buy |
2,063
+900
| +77% | +$128K | ﹤0.01% | 3958 |
|
|
2017
Q2 | $174K | Sell |
1,163
-119
| -9% | -$16.4K | ﹤0.01% | 4026 |
|
|
2017
Q1 | $200K | Buy |
1,282
+1,051
| +455% | +$185K | ﹤0.01% | 4075 |
|
|
2016
Q4 | $48K | Sell |
231
-32
| -12% | -$6.65K | ﹤0.01% | 4561 |
|
|
2016
Q3 | $60K | Sell |
263
-153
| -37% | -$35.4K | ﹤0.01% | 3992 |
|
|
2016
Q2 | $86K | Buy |
416
+410
| +6,833% | +$99.2K | ﹤0.01% | 3901 |
|
|
2016
Q1 | $1K | Buy |
+6
| New | +$1.38K | ﹤0.01% | 4555 |
|
JP Morgan Chase's CDTX Position: Q1 2026 in Review
JP Morgan Chase sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 276,551 shares — an estimated $61.1M sold.
JP Morgan Chase first reported a position in CDTX in Q1 2016 and held it in 38 quarters. The position peaked at $61.1M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- JP Morgan Chase reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- JP Morgan Chase sold 276,551 Cidara Therapeutics shares in Q1 2026, an estimated $61.1M.
- JP Morgan Chase first reported a position in Cidara Therapeutics in Q1 2016 and held it in 38 quarters.
- JP Morgan Chase's Cidara Therapeutics position peaked at $61.1M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.